vimarsana.com
Home
Live Updates
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia : vimarsana.com
Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
BOSTON & ZUG, Switzerland--(BUSINESS WIRE)--Nov 16, 2023--
Related Keywords
United States ,
Boston ,
Massachusetts ,
United Kingdom ,
Australia ,
Switzerland ,
London ,
City Of ,
San Francisco ,
California ,
Saudi Arabia ,
Kingdom Of Saudi Arabia ,
Saudi ,
America ,
Great Britain ,
Samarth Kulkarni ,
Rachel Eides ,
Reshma Kewalramani ,
Heather Nichols ,
Susan Kim ,
Manisha Pai ,
Instagram ,
Exchange Commission ,
Vertex Pharmaceuticals Incorporated ,
Regulatory Agency ,
Linkedin ,
Drug Administration ,
Companies To Work ,
Facebook ,
Drug Authority ,
Youtube ,
Vertex Pharmaceuticals Incorporated Nasdaq ,
Consultant Haematologist At Imperial College Healthcare ,
Viacyte Inc ,
European Hematology Association Congress ,
Therapeutics Inc ,
Vertex Pharmaceuticals ,
European Medicines Agency ,
Pharmaceuticals Incorporated ,
Chief Executive Officer ,
Nobel Prize ,
Professor Josu De La Fuente ,
Principal Investigator ,
Gene Therapy ,
Imperial College London ,
Consultant Haematologist ,
Imperial College Healthcare ,
Innovation Passport ,
Innovative Licensing ,
Access Pathway ,
Saudi Food ,
Priority Review ,
Standard Review ,
Prescription Drug User Fee Act ,
North America ,
Top Employers ,
Private Securities Litigation Reform Act ,
While Vertex ,
Business Wire ,
Region ,
vimarsana.com © 2020. All Rights Reserved.